The LumaGEM Molecular Breast Imaging (MBI) business of Gamma Medica Inc has been acquired through a chapter 11 sale by Imaging Acquisition Inc, an entity controlled by health care growth equity firm Psilos Group Managers LLC.
Psilos, which has approximately $600 million under its management, has been an investor in Gamma Medica since 2009. Eichler and Psilos senior managing member Albert S. Waxman, PhD, will serve on the Gamma Medica board of directors.
LumaGEM highlights tumors, even those obscured by dense breast tissue. LumaGEM’s 91% sensitivity and 93% specificity when used in conjunction with mammography allows physicians to detect cancer earlier, especially in the approximately 40% of women who have dense breasts.